Dr. Hay is a Hematologist and clinician scientist within the Department of Medicine, cross appointed to the Department of Oncology, and a Senior Investigator with the Canadian Cancer Trials Group. Having completed medical and hematology training in Scotland, Dr. Hay undertook 2 ½ years of fellowship with the Canadian Cancer Trials Group, transitioning to a Senior Investigator position in 2014. In this role her responsibilities include development and conduct of clinical trials for patients with hematological malignancies, economic evaluations of cancer interventions, and improving opportunities for adolescents and young adults with cancer to participate in clinical research. Interests also include exploration of more efficient means to conduct clinical trials, whilst upholding patient privacy and safety.
Areas of expertise:Clinical trials, myeloma, lymphoma, leukemia, data sharing and linkage, adolescents and young adults with cancer, health economics, CAR T-cell therapy
Research interests: Clinical trials, myeloma, lymphoma, leukemia, CAR T-cell therapy, data sharing and linkage, health economics
Current trials: MYX1, IND216, SI612 (ALC5), CLC2E, SRC6, LY15, LY17, LY18
Hay AE, Klimm B, Chen BE, Goergen H, Shepherd LE, Fuchs M, Gospodarowicz M, Borchmann P, Connors JM, Markova J, Crump M, Lohri A, Winter JN, Dörken B, Pearcey RG, Diehl V, Horning SJ, Eich HT, Engert A, Meyer RM. An individual patient-data comparison of combined-modality therapy and ABVD alone for patients with limited-stage Hodgkin Lymphoma. Annals of Oncology 2013; 24(12): 3065-9.
Crump M, Neelapu SS, Farooq U, Van Den Neste E, Kuruvilla J, Westin J, Link BK, Hay AE, Cerhan JR, Zhu L, Boussetta S, Feng L, Maurer MJ, Navale L, Wiezorek J, Go WY, Gisselbrecht C. Outcomes in refractory diffuse large B cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017; 130(16):1800-1808.
Hay AE, Pater JL, Corn E, Han L, Camacho X, O’Callaghan C, Chong N, Bell EN, Tu D, Earle C. Pilot study of the ability to probabilistically link clinical trial patients to administrative data and determine long-term outcomes. Clinical Trials2019:16(1):14-17.
Hay AE, Murugesan A, DiPasquale AM, Kouroukis T, Sandhu I, Kukreti V, Bahlis NJ, Lategan J, Reece DE, Lyons JF, Sederias J, Xu H, Powers J, Seymour LK, Reiman T. A phase II study of AT9283, an Aurora Kinase Inhibitor, in patients with relapsed or refractory multiple myeloma: NCIC Clinical Trials Group IND191. Leukemia and Lymphoma 2016; 57(6): 1463-6.
Cheung WY, Kornelsen E, Mittmann N, Leighl NB, Cheung MC, Chan KK, Bradbury PA, Ng RCH, Chen BE, Ding K, Pater JL, Tu D, Hay AE. The economic impact of the transition from branded to generic oncology drugs. Current Oncology2019;26(2):89-93.
- American Society of Hematology Abstract Achievement Award, 2012
- Canadian Hematology Society John H. Crookston Award, 2012
- Inaugural recipient of NCIC Clinical Trials Group Ralph Meyer Phase III Young Investigator Award, 2014
- Queen’s University Internal Medicine Subspecialty Teaching Award, 2015
For a full list of publications please visit PubMed.